Zhipin Liang

Zhipin Liang

Auto-generated profile, based on publicly available information

Zhipin Liang

Department of Interdisciplinary Oncology, School of Medicine, LSU LCMC Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
CZChao Zhang
Chao Zhang
XKXiaohong Kong
Xiaohong Kong
CLChang Liu
Chang Liu
ZLZhipin Liang
Zhipin Liang
HZHuabing Zhao
Huabing Zhao
SFShiqing Feng
Shiqing Feng

1 May 2021 in Genes & Diseases
Verified
Journal Article
Open access
HZHongyou Zhao
Hongyou Zhao
BYBin Yi
Bin Yi
ZLZhipin Liang
Zhipin Liang
CPChes’nIque Phillips
Ches’nIque Phillips
HLHui-Yi Lin
Hui-Yi Lin
YXYaguang Xi
Yaguang Xi
Sulindac has shown significant clinical benefit in preventing colorectal cancer progression, but its mechanism of action has not been fully elucidated. We have found that sulindac sulfide (SS) is able to inhibit cell cycle progression in human colorectal cancer cells, particularly through G1 arrest. To understand the underlying mechanisms of sulindac inhibitory activity, we have demonstrated that Cyclin G2 up-regulation upon SS treatment can substantially delay cell cycle progression by enhancing the transcriptional activity of FOXO3a in human colorectal tumor cells. MiR-182, an oncogenic microRNA known to inhibit FOXO3a gene expression, is also involved in the suppressive effect of SS on cell cycle progression. This process begins with the down-regulation of miR-182, followed by the enhancement of FOXO3a transcriptional activity and the up-regulation of Cyclin G2. To further determine the clinical utility of this axis, we analyzed the expression of miR-182/FOXO3a/Cyclin G2 in human colorectal tumor samples. Our results show not only that there are significant differences in miR-182/FOXO3a/Cyclin G2 between tumors and normal tissues, but also that the synergetic effect of miR-182 and FOXO3a is associated with predicting tumor progression. Our study demonstrates a novel mechanistic axis consisting of miR-182/FOXO3a/Cyclin G2 that mediates sulindac inhibition of cell cycle progression.

18 October 2020 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
ZLZhipin Liang
Zhipin Liang
ZQZhiqiang Qin
Zhiqiang Qin
ARAdam I. Riker
Adam I. Riker
YXYaguang Xi
Yaguang Xi

1 November 2025 in Genes & Diseases
Verified
Journal Article
Open access
CLCaiyue Li
Caiyue Li
ZLZhipin Liang
Zhipin Liang
GVGabrielle Vontz
Gabrielle Vontz
CKConnor Kent
Connor Kent
WMWenbo Ma
Wenbo Ma
QSQiang Shen
Qiang Shen
CISD1, an outer mitochondrial membrane iron-sulfur cluster protein, regulates intracellular iron levels, oxidative stress, and mitochondrial dynamics, playing critical roles in cellular bioenergetics and redox homeostasis. Although CISD1 has been identified as a prognostic biomarker in specific cancers, its broader implications in tumorigenesis, cancer progression, and immunotherapy remain unclear. Given the heterogeneity of cancer and the need for robust biomarkers across cancers, this study conducts the first comprehensive pan-cancer analysis of CISD1 by evaluating its roles in cancer and treatment. We obtained and analyzed data from databases including TCGA, GTEx, THPA, GEPIA2.0, SangerBox, cBioPortal, TIMER2.0, CAMOIP, DAVID, SRPLOT, and TISIDB. Our findings reveal significant alterations in CISD1 expression at both transcriptional and translational levels, as well as gene mutations across multiple cancers, indicating its potential as a diagnostic biomarker and its involvement in cancer development and progression. CISD1 dysregulation is linked to poor clinical outcomes, as shown through its impact on patient prognosis. GO and KEGG analyses show that CISD1 plays critical roles in cellular bioenergetics. Notably, CISD1 expression is significantly correlated with tumor stemness indices, tumor mutation burden, microsatellite instability, and immune checkpoint proteins in multiple cancers, and altered CISD1 levels are also observed in patients responding to immunotherapy, further supporting its role not only in prognosis but also as a key predictor in immunotherapy responses and outcomes. Our findings demonstrate CISD1 as a reliable and promising diagnostic, prognostic, and immunotherapeutic biomarker for multiple cancers, emphasizing its crucial role in cancer biology and potential to guide personalized cancer therapies.